ArticleActa pharmaceutica Sinica. B2023
A potentially serious adverse effect of GLP-1 receptor agonists.
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.Journal of Crohn's & colitis · 2025 · on this mapPooled it
- Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies.Current obesity reports · 2026Review
- Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review.Journal of obesity & metabolic syndrome · 2026Review
- Association of GLP-1 receptor agonists with risk of intestinal obstruction in patients with type 2 diabetes mellitus: a retrospective cohort study.Acta diabetologica · 2025Article
- Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice.Pharmacological research · 2025Article
- Astragalus Mongholicus Polysaccharides Alleviate Kidney Injury in Rats with Type 2 Diabetes Through Modulation of Oxidation, Inflammation, and Gut Microbiota.International journal of molecular sciences · 2025Article
- Intestinal stearoyl-coenzyme A desaturase-inhibition improves obesity-associated metabolic disorders.Acta pharmaceutica Sinica. B · 2025Article
- Article
- The therapeutic effects and mechanisms of glucagon-like peptide-1 receptor agonists in neurocognitive disorders.Therapeutic advances in neurological disorders · 2025Review
- Management of Overweight and Obesity in Patients With Inflammatory Bowel Disease.Gastroenterology & hepatology · 2024Article
- Does Incretin Agonism Have Sustainable Efficacy?Cells · 2024Review
- Tirzepatide-Associated Colonic Ischemia.ACG case reports journal · 2024Article
- Surgical or medical treatment of obesity-associated type 2 diabetes-an increasing clinical conundrum.World journal of diabetes · 2024Article
- Food-induced small bowel obstruction observed in a patient with inappropriate use of semaglutide.Diabetology international · 2024Article
- A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment.Pharmacological reports : PR · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.